Rapport Therapeutics (RAPP) Profit After Tax (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Profit After Tax data on file, last reported at -$19.9 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 4760.42% year-over-year to -$19.9 million in Q1 2026; TTM through Mar 2026 was -$107.3 million, a 571.67% decrease from a year earlier, with the FY2025 full-year figure at -$111.5 million, down 21097.72% from the prior year.
• Profit After Tax for Q1 2026 stood at -$19.9 million, up from -$33.8 million in the prior quarter.
• Over the last five years, Profit After Tax for RAPP reached as high as $57.4 million in Q4 2024 and fell as low as -$33.8 million in Q4 2025.
• Historically, Profit After Tax has averaged -$11.3 million across 4 years, with a median of -$17.5 million in 2024.
• Across the five-year window, Profit After Tax jumped 524.62% in 2024 and tumbled 4760.42% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$13.5 million in 2023, then soared by 524.62% to $57.4 million in 2024, then slumped by 158.85% to -$33.8 million in 2025, then surged by 41.09% to -$19.9 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$19.9 million in Q1 2026, -$33.8 million in Q4 2025, and -$26.9 million in Q3 2025.